• 靶点：
• Cyclin L1

• 基因名称：
• CCNL1

• 蛋白名称：
• Cyclin-L1

• Human Gene Id：
• 57018

• Human Swiss Prot No：
• Q9UK58

• Mouse Gene Id：
• 56706

• Mouse Swiss Prot No：
• Q52KE7

• Rat Gene Id：
• 1.0091e+008

• Rat Swiss Prot No：
• Q9R1Q2

• 免疫原：
• The antiserum was produced against synthesized peptide derived from human Cyclin L1. AA range:461-510

• 特异性：
• Cyclin L1 Polyclonal Antibody detects endogenous levels of Cyclin L1 protein.

• 组成：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• 来源：
• Polyclonal, Rabbit,IgG

• 稀释：
• WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:10000.. IF 1:50-200

• 纯化工艺：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• 浓度：
• 1 mg/ml

• 储存：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• 其他名称：
• CCNL1;BM-001;Cyclin-L1;Cyclin-L

• 实测条带：
• 60kD

• 背景：
• alternative products:Ccnl1 is an immediate-early gene with independently regulated isoforms,domain:Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions.,function:Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II). Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.,miscellaneous:CCNL1 is amplified in several HNSCC. May play a critical role in the formation of loco-regional metastases and an unfavorable clinical outcome of HNSCC.,sequence caution:Probable cloning artifact.,similarity:Belongs to the cyclin family. Cyclin L subfamily.,subcellular location:More specifically found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing.,subunit:Interacts with POLR2A via its hyperphosphorylated C-terminal domain (CTD) (By similarity). Interacts with CDC2L1 or CDC2L2, and SFRS2.,tissue specificity:Ubiquitous with higher level in thymus. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC).,

• 功能：
• alternative products:Ccnl1 is an immediate-early gene with independently regulated isoforms,domain:Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions.,function:Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II). Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.,miscellaneous:CCNL1 is amplified in several HNSCC. May play a critical role in the formation of loco-regional metastases and an unfavorable clinical outcome of HNSCC.,sequence cauti

• 细胞定位：
• Nucleus speckle . Nucleus, nucleoplasm . Found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing. .

• 组织表达：
• Widely expressed. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC).

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs